Vedanta Makes Two New Appointments
This article was originally published in Scrip
Vedanta Biosciences has appointed Lisa Rae Schopf head of preclinical development and Erick J. Spek head of intellectual property. Schopf joins Vedanta from Kala Pharmaceuticals where she was senior director of preclinical development and has also previously worked at Virdante Pharmaceuticals, Abbott Bioresearch Centre, Millennium and Genetics Institute. Prior to joining Vedanta, Spek was director of IP at Epizyme, Inc. and before this he worked at Wolf Greenfield, an IP law firm.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.